NCT01799083

Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas

Phase 1/2 Study of Decitabine Alone and/or in Combination With Chemotherapy and/or Cytokine Induced Killer Cell Transfusion in Patients With Relapsed or Refractory Solid Tumors and B Cell Lymphomas

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Han weidong · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Determine alone or in combination with chemotherapy or autologous cytokine induced killer cells are effective and safe in the treatment of patients with relapsed and/or refractory solid tumors or B Cell lymphomas.

Detailed description

The purpose of this study is to determine whether lower dose decitabine based therapy is safe and can effectively control tumor progression.

Conditions

• Solid Tumors
• B Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Decitabine	A continuous 5-day lower-dose decitabine transfusion will be performed for patients during each treatment cycle, and autologous cytokine-induced killer cells may be transfused or chemotherapy may be also added.
BIOLOGICAL	cytokine-induced killer cell	Autologous cytokine-induced killer cells may be used for patients before and after decitabine treatment.

Timeline

• Start date: 2012-12-01
• Primary completion: 2016-12-01
• Completion: 2017-12-01
• First posted: 2013-02-26
• Last updated: 2016-01-28

Locations

1 site across 1 country: China